Blair William & CO Ocuphire Pharma, Inc. Call Options Transaction History
Blair William & CO
- $32 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OCUP
# of Institutions
44Shares Held
2.54MCall Options Held
2KPut Options Held
2K-
Vanguard Group Inc Valley Forge, PA992KShares$1.15 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA266KShares$308,3900.0% of portfolio
-
Richmond Brothers, Inc. Jackson, MI191KShares$221,9120.6% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX164KShares$189,9390.01% of portfolio
-
Black Rock Inc. New York, NY107KShares$124,0440.0% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $23.9M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...